Last reviewed · How we verify
Evolocumab Pre-filled Syringe
Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular events), Familial hypercholesterolemia.
At a glance
| Generic name | Evolocumab Pre-filled Syringe |
|---|---|
| Also known as | AMG 145, Repatha |
| Sponsor | Amgen |
| Drug class | PCSK9 inhibitor (monoclonal antibody) |
| Target | PCSK9 |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
PCSK9 is a protein that degrades LDL receptors on liver cells, reducing the liver's ability to remove LDL cholesterol from blood. By binding to and inhibiting PCSK9, evolocumab prevents this degradation, allowing more LDL receptors to remain on hepatocyte surfaces. This results in enhanced uptake and clearance of LDL cholesterol, significantly lowering blood LDL levels.
Approved indications
- Hypercholesterolemia (primary and secondary prevention of cardiovascular events)
- Familial hypercholesterolemia
Common side effects
- Injection site reactions
- Nasopharyngitis
- Upper respiratory tract infection
- Influenza
- Back pain
Key clinical trials
- Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study) (PHASE2)
- Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Evolocumab Pre-filled Syringe CI brief — competitive landscape report
- Evolocumab Pre-filled Syringe updates RSS · CI watch RSS
- Amgen portfolio CI